Evgen Pharma PLC Total Voting Rights (7759A)
03 January 2018 - 4:44AM
UK Regulatory
TIDMEVG
RNS Number : 7759A
Evgen Pharma PLC
02 January 2018
2 January 2018
Evgen Pharma plc
("Evgen Pharma" or "the Company")
Total Voting Rights
Evgen Pharma (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, makes the following notification in accordance with the
FCA's Disclosure Guidance and Transparency Rule 5.6.1.
As at 29 December 2017 the Company's issued share capital
consists of 93,276,858 Ordinary Shares of 0.25p each.
The total number of voting rights in the Company is 93,276,858
and this figure may be used by shareholders as the denominator for
the calculations by which they should determine if they are
required to notify their interest in, or change to their interest
in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.
Enquiries
Evgen Pharma plc c/o +44 (0) 20 7466 5000
Dr Stephen Franklin, CEO
Richard Moulson, CFO
www.evgen.com
Buchanan
Mark Court, Sophie Wills, Stephanie Watson +44 (0) 20 7466 5000
Northland Capital Partners Limited
Matthew Johnson, Gerry Beaney (Corporate Finance)
John Howes, Rob Rees (Corporate Broking) +44 (0) 20 3861 6625
Notes for editors
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose
lead programmes are in breast cancer and subarachnoid haemorrhage,
a type of stroke. The Company's core technology is Sulforadex(R), a
method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. It joined the
AIM market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVRDLLFBVFFZBBL
(END) Dow Jones Newswires
January 02, 2018 12:44 ET (17:44 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2024 to May 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From May 2023 to May 2024